drugset / Trial / NCT02503540

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540

Phase 4 Completed 31 enrolled Justis Ehlers Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

This interventional study will evaluate the retinal vascular dynamics associated with Intravitreal Aflibercept Injection (IAI) therapy in eyes with diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO). Ultra-widefield fluorescein angiography and optical coherence tomography (OCT) angiography will be performed at multiple timepoints to assess the changes in retinal vascular leakage, ischemia, and vascular abnormalities throughout the study duration and compare these alterations to baseline.

Timeline

Start
2015-08-18
Primary completion
2018-02-06
Completion
2018-02-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal